专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL282433D0 5-membered heteroaryl carboxamide compounds for treatment of hbv 未知
公开(公告)号：IL282433D0
公开(公告)日：2021-06-30
申请号：IL28243321
申请日：2021-04-19
申请人： ASSEMBLY BIOSCIENCES INC , HAYDAR SIMON NICOLAS , LI LEPING , BURES MARK G , RAI ROOPA , BANNEN LYNNE , WALKER MICHAEL
发明人： HAYDAR SIMON NICOLAS , LI LEPING , BURES MARK G , RAI ROOPA , BANNEN LYNNE , WALKER MICHAEL
IPC分类号： A61P31/12
摘要： The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

2. 发明专利

IL297305A 5-membered heteroaryl carboxamide compounds for treatment of hbv 未知
公开(公告)号：IL297305A
公开(公告)日：2022-12-01
申请号：IL29730522
申请日：2022-10-13
申请人： ASSEMBLY BIOSCIENCES INC , HECKRODT THILO , WALKER MICHAEL , ZHONG MIN
发明人： HECKRODT THILO , WALKER MICHAEL , ZHONG MIN
IPC分类号： A61P31/12
摘要： The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

3. 发明专利

SG11202104086PA 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV 未知
公开(公告)号：SG11202104086PA
公开(公告)日：2021-05-28
申请号：SG11202104086P
申请日：2019-10-22
申请人： ASSEMBLY BIOSCIENCES INC
发明人： HAYDAR SIMON , LI LEPING , BURES MARK , RAI ROOPA , BANNEN LYNNE , WALKER MICHAEL
IPC分类号： A61P31/12 , A61K31/4155 , C07D231/38 , C07D401/10 , C07D403/04 , C07D403/08 , C07D403/10 , C07D405/04 , C07D409/04 , C07D413/08 , C07D417/08 , C07D417/10
摘要： The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

4. 发明专利

CA3117449A1 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV 未知
公开(公告)号：CA3117449A1
公开(公告)日：2020-04-30
申请号：CA3117449
申请日：2019-10-22
申请人： ASSEMBLY BIOSCIENCES INC
发明人： HAYDAR SIMON NICOLAS , LI LEPING , BURES MARK G , RAI ROOPA , BANNEN LYNNE , WALKER MICHAEL
IPC分类号： C07D231/38 , A61K31/395 , A61K31/415 , A61K31/4178 , A61K31/422 , A61K31/423 , A61K31/427 , A61K31/435 , A61K31/4439 , A61K31/496 , A61K31/5377 , A61K31/551 , A61P31/20 , C07D401/04 , C07D403/04 , C07D403/08 , C07D405/04 , C07D409/04 , C07D413/04 , C07D413/08 , C07D417/08
摘要： The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

5. 发明专利

AU2019364352A1 5-membered heteroaryl carboxamide compounds for treatment of HBV 未知
公开(公告)号：AU2019364352A1
公开(公告)日：2021-06-03
申请号：AU2019364352
申请日：2019-10-22
申请人： ASSEMBLY BIOSCIENCES INC
发明人： HAYDAR SIMON NICOLAS , LI LEPING , BURES MARK G , RAI ROOPA , BANNEN LYNNE , WALKER MICHAEL
IPC分类号： A61P31/12 , A61K31/4155 , C07D231/38 , C07D401/10 , C07D403/04 , C07D403/08 , C07D403/10 , C07D405/04 , C07D409/04 , C07D413/08 , C07D417/08 , C07D417/10
摘要： The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

6. 发明专利

AU2021261307A1 5-membered heteroaryl carboxamide compounds for treatment of HBV 未知
公开(公告)号：AU2021261307A1
公开(公告)日：2022-11-17
申请号：AU2021261307
申请日：2021-04-21
申请人： ASSEMBLY BIOSCIENCES INC
发明人： HECKRODT THILO , WALKER MICHAEL , ZHONG MIN
IPC分类号： C07D401/08 , A61K31/4164 , A61P31/12 , C07D233/90 , C07D403/08 , C07D471/04 , C07D487/04 , C07D498/04
摘要： The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

7. 发明专利

PH12021550887A1 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV 未知
公开(公告)号：PH12021550887A1
公开(公告)日：2022-02-21
申请号：PH12021550887
申请日：2021-04-21
申请人： ASSEMBLY BIOSCIENCES INC
发明人： HAYDAR SIMON NICOLAS , LI LEPING , BURES MARK G , RAI ROOPA , BANNEN LYNNE , WALKER MICHAEL
IPC分类号： C07D405/04 , A61K31/4155 , A61P31/12 , C07D231/38 , C07D401/10 , C07D403/04 , C07D403/08 , C07D403/10 , C07D409/04 , C07D413/08 , C07D417/08 , C07D417/10
摘要： The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

8. 发明专利

AR116800A1 COMPUESTOS DE HETEROARIL CARBOXAMIDA DE 5 MIEMBROS PARA EL TRATAMIENTO DEL VHB 未知
公开(公告)号：AR116800A1
公开(公告)日：2021-06-16
申请号：ARP190103019
申请日：2019-10-22
申请人： ASSEMBLY BIOSCIENCES INC
发明人： WALKER MICHAEL , BANNEN LYNNE , RAI ROOPA , BURES MARK G , LI LEPING , HAYDAR SIMON NICOLAS
IPC分类号： C07D231/38 , A61K31/4155 , A61P31/12 , C07D401/10 , C07D403/04 , C07D403/08 , C07D403/10 , C07D405/04 , C07D409/04 , C07D413/08 , C07D417/08 , C07D417/10
摘要： Esta divulgación proporciona, en parte, compuestos de heteroaril carboxamida de 5 miembros y composiciones farmacéuticas de esto, que son útiles para interrumpir el ensamblaje de la proteína central del VHB, así como métodos para tratar la infección por hepatitis B (VHB). Reivindicación 1: En un aspecto, se indica en la presente un compuesto de fórmula (1), una sal de este aceptable en términos farmacéuticos, donde: X¹ es NRˣ¹, O ó S; X² es N o CRˣ²; X³ es O, NR⁷, CR⁴R⁸, C(O), S(O)ₜ, C=CR⁴R⁰ o C=NR⁴; X⁴ y X⁶ son independientemente O ó S; X⁵ es O, S o NR⁰; L es un enlace o C₁₋₆ alquileno; L¹ es un enlace, C₁₋₆ alquileno, O, NRᶜ, C(O), C(O)NRᶜ, S(O)ₜ o S(O)ₜNRᶜ; Rˣ¹ y Rˣ² están seleccionados de manera independiente del grupo que consiste en hidrógeno, C₁₋₆ alquilo, haloC₁₋₆ alquilo y C₃₋₆ monocicloalquilo; Rᵃ, Rᵇ y Rᶜ están seleccionados de manera independiente para cada surgimiento del grupo que consiste en hidrógeno, C₁₋₆ alquilo, haloC₁₋₆ alquilo y C₃₋₆ monocicloalquilo; Rᵈ es hidrógeno, OH, C₁₋₆ alquilo o C₁₋₆ alcoxi; R⁰, R⁶, R⁸ y R¹¹ se seleccionan independientemente para cada ocurrencia a partir del grupo que consta de hidrógeno, halógeno, OH, CN, NO₂, oxo, RᵈN=, hidrazino, formilo, azida, silil, siloxi, HOC(O)-, RᵃRᵇN-, RᵃRᵇNS(O)ₜ-, C₁₋₆ alquilo, C₂₋₆ alquenil, C₂₋₆ alquinil, C₃₋₆ monocicloalquilo, haloC₁₋₆ alquilo, hidroxiC₁₋₆ alquilo-, RᵃRᵇNC₁₋₆ alquilo-, HOC(O)C₁₋₆ alquilo-, RᵃRᵇNC₁₋₆ alquiloNRᶜ-, C₁₋₆ alquiloNRᵃC₁₋₆ alquiloNRᶜ-, C₁₋₆ alcoxi, haloC₁₋₆ alcoxi, hidroxiC₁₋₆ alcoxi-, RᵃRᵇNC₁₋₆ alcoxi-, C₁₋₆ alcoxiC₁₋₆ alquilo-, haloC₁₋₆ alcoxiC₁₋₆ alquilo-, RᵃRᵇNC(O)-, C₁₋₆ alquiloC(O)-, C₁₋₆ alcoxiC(O)-, C₁₋₆ alquiloC(O)O-, C₁₋₆ alquiloS(O)q-, C₁₋₆ alquiloS(O)ₜNRᶜ-, C₁₋₆ alquiloS(O)ₜC₁₋₆ alquilo-, C₁₋₆ alquiloS(O)ₜNRᵃC₁₋₆ alquilo-, C₃₋₆ cicloalquiloS(O)ₜC₁₋₆ alquilo-, C₁₋₆ alquiloC(O)C₁₋₆ alquilo-, y C₁₋₆ alquiloC(O)OC₁₋₆ alquilo-; R⁰ᵃ está seleccionado de manera independiente para cada surgimiento del grupo que consiste en hidrógeno, halógeno, OH, CN, NO₂, RᵃRᵇN-, C₁₋₆ alquilo y haloC₁₋₆ alquilo; R¹ es un fenilo, naftilo, C₃₋₆ monocicloalquilo, C₃₋₆ monoheterocicloalquilo o heteroarilo monocíclico de 5 - 6 miembros, donde: el fenilo, C₃₋₆ monocicloalquilo, C₃₋₆ monoheterocicloalquilo o heteroarilo monocíclico de 5 - 6 miembros se sustituye opcionalmente por uno, dos o tres grupos R¹¹ seleccionados de manera independiente; R² es hidrógeno, halógeno, RᵃRᵇN, C₁₋₆ alquilo, haloC₁₋₆ alquilo, C₃₋₆ monocicloalquilo o C₁₋₆ alcoxi; R³ se selecciona a partir del grupo que consiste en los compuestos del grupo de fórmulas (2); R⁴ es R⁵, R⁶ o R⁵-L¹-; R⁴ y R⁸ juntos con el átomo de carbono al que están unidos forman un grupo de fórmula (3) ó (4); R⁴ᵃ es hidrógeno o C₁₋₆ alquilo; R⁴ᵇ es R⁵, R⁵ᵃ, R⁶ o R⁵-L¹-; R⁵ se selecciona del grupo que consiste en los compuestos del grupo de fórmulas (5); R⁵ᵃ es un resto de fórmula (6); R⁵ᵇ es un compuesto seleccionado del grupo de fórmulas (7); R⁶ᵃ es hidrógeno o C₁₋₆ alquilo; R⁷ es hidrógeno, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ alcoxiC₁₋₆ alquilo-, NRᵃRᵇC(O)-, R⁷ᵃC(O)-, C₁₋₆ alquiloxiC(O)-, C₁₋₆ alquiloS(O)q- o C₁₋₆ haloalquiloS(O)q-; R⁷ᵃ es C₁₋₆ alquilo o C₃₋₆ monocicloalquilo; q, r, t y w se seleccionan de manera independiente para cada surgimiento de 0, 1 y 2; y v se selecciona de manera independiente para cada surgimiento de 0, 1, 2 y 3.

9. 发明申请

WO2010003021A3 CHARGING STATIONS FOR ELECTRIC VEHICLES 审中-公开
标题翻译：电动车充电站
公开(公告)号：WO2010003021A3
公开(公告)日：2010-03-11
申请号：PCT/US2009049448
申请日：2009-07-01
申请人： PROTERRA LLC , HILL DALE , WALKER MICHAEL , GOLDMAN JOSHUA , HORTH JOHN
发明人： HILL DALE , WALKER MICHAEL , GOLDMAN JOSHUA , HORTH JOHN
IPC分类号： B60L11/18
CPC分类号： B60M7/003 , B60L5/005 , B60L5/42 , B60L11/1816 , B60L11/1824 , B60L11/1825 , B60L11/1827 , B60L11/1837 , B60L11/185 , B60L2200/18 , B60L2200/26 , H02J7/0021 , H02J7/0042 , H02J7/007 , Y02T10/7005 , Y02T10/7072 , Y02T10/7088 , Y02T90/121 , Y02T90/128 , Y02T90/14
摘要： The invention relates to systems and methods for charging a vehicle. A vehicle and charging station can be designed such that an electric or hybrid vehicle can operate in a fashion similar to a conventional vehicle by being opportunity charged throughout a known route.
摘要翻译：本发明涉及用于给车辆充电的系统和方法。车辆和充电站可以被设计成使得电动车辆或混合动力车辆可以通过在已知路线中充电机会而以类似于常规车辆的方式操作。

10. 发明专利

AU2013274071A1 System and methods for communicating between multiple access devices 未知
公开(公告)号：AU2013274071A1
公开(公告)日：2015-02-05
申请号：AU2013274071
申请日：2013-06-14
申请人： MEECH DANIEL , WALKER MICHAEL , HENCHER NICHOLAS , THOMSON REUTERS GLO RESOURCES , BENNETT DANIEL , PIRCHER PETER
发明人： WALKER MICHAEL , MEECH DANIEL , HENCHER NICHOLAS , PIRCHER PETER , BENNETT DANIEL
IPC分类号： H04L12/58
摘要： A method includes verifying, via an application chat server, an association between a first access device and a second access device, wherein the first access device and the second access device associated with a first statement of task capability and a second statement of task capability, respectively. The method further includes analyzing, based upon one or more of the first and second statements of task capability, a task command to determine that the second access device is capable of executing at least one task. The method further includes generating, in response to the determining, an execution command, wherein the execution command associated with the at least task and transmitting an execution signal, wherein the execution signal associated with the execution command.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式